HighLight Capital

HighLight Capital is a leading Chinese venture capital and private equity firm specializing in healthcare investments. Founded in 2014 and headquartered in Shanghai (with additional presence noted in Nanjing), it focuses on early to expansion-stage investments across biopharma, medtech, medical devices, diagnostics, healthcare services and consumer health. The firm has backed over 150 companies with more than $1 billion under management. Its portfolio includes innovative biotech firms such as Imago BioSciences (hematology small molecules), Nuevocor (gene therapy for cardiovascular disease), Etana and UBC (biologics/API/IVD manufacturing). HighLight actively supports its portfolio’s international expansion—especially into Southeast Asia—and frequently collaborates with global investors like Temasek and Sequoia China.